NTLA
Intellia Therapeutics, Inc.NASDAQHealthcare$13.13-1.06%ClosedMarket Cap: $1.55B
As of 2026-04-06
Valuation
P/E (TTM)
—
PEG
—
P/B
2.12
P/S
22.92
EV/EBITDA
-3.57
DCF Value
$-16.82
FCF Yield
-25.5%
Div Yield
0.0%
Margins & Returns
Gross Margin
-25.6%
Operating Margin
-651.7%
Net Margin
-609.9%
ROE
-56.6%
ROA
-49.0%
ROIC
-57.7%
Income Statement
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q4 2025 | $23.0M | 73.9% | $-98.7M | $-95.8M | $-0.83 | — |
| FY 2025 | $67.7M | 76.5% | $-441.0M | $-412.7M | $-3.81 | — |
| Q3 2025 | $13.8M | -472.8% | $-111.5M | $-101.3M | $-0.92 | — |
| Q2 2025 | $14.2M | 100.0% | $-110.0M | $-101.3M | $-0.98 | — |
| Q1 2025 | $16.6M | 100.0% | $-120.8M | $-114.3M | $-1.10 | — |
| Q4 2024 | $12.9M | 100.0% | $-136.4M | $-128.9M | $-1.27 | — |
| FY 2024 | $57.9M | 82.2% | $-534.3M | $-519.0M | $-5.25 | — |
| Q3 2024 | $9.1M | 100.0% | $-144.8M | $-135.7M | $-1.34 | — |
| Q2 2024 | $7.0M | 62.6% | $-139.0M | $-147.0M | $-1.52 | — |
| Q1 2024 | $28.9M | 91.3% | $-114.0M | $-107.4M | $-1.12 | — |
| Q4 2023 | $-1.9M | 228.6% | $-139.9M | $-132.2M | $-1.46 | — |
| FY 2023 | $36.3M | 75.3% | $-515.3M | $-481.2M | $-5.42 | — |